JP6880307B2 - 終末糖化産物の低減活性を有する新規な菌株およびその用途 - Google Patents
終末糖化産物の低減活性を有する新規な菌株およびその用途 Download PDFInfo
- Publication number
- JP6880307B2 JP6880307B2 JP2020504082A JP2020504082A JP6880307B2 JP 6880307 B2 JP6880307 B2 JP 6880307B2 JP 2020504082 A JP2020504082 A JP 2020504082A JP 2020504082 A JP2020504082 A JP 2020504082A JP 6880307 B2 JP6880307 B2 JP 6880307B2
- Authority
- JP
- Japan
- Prior art keywords
- strain
- present
- advanced glycation
- glycation end
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010005094 Advanced Glycation End Products Proteins 0.000 title claims description 66
- 230000001603 reducing effect Effects 0.000 title claims description 37
- 239000000047 product Substances 0.000 claims description 77
- 239000000203 mixture Substances 0.000 claims description 32
- 235000013305 food Nutrition 0.000 claims description 30
- 239000004480 active ingredient Substances 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 244000063299 Bacillus subtilis Species 0.000 claims description 15
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 15
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 15
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000006041 probiotic Substances 0.000 claims description 13
- 235000018291 probiotics Nutrition 0.000 claims description 13
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 208000019553 vascular disease Diseases 0.000 claims description 11
- 208000020832 chronic kidney disease Diseases 0.000 claims description 10
- 230000000968 intestinal effect Effects 0.000 claims description 10
- 241000186660 Lactobacillus Species 0.000 claims description 9
- 229940039696 lactobacillus Drugs 0.000 claims description 9
- 230000000529 probiotic effect Effects 0.000 claims description 9
- 206010007749 Cataract diabetic Diseases 0.000 claims description 8
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 8
- 201000007025 diabetic cataract Diseases 0.000 claims description 8
- 208000019622 heart disease Diseases 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 7
- 230000033228 biological regulation Effects 0.000 claims description 6
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 5
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 241000194035 Lactococcus lactis Species 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- OQVOZFPJUCUPLW-LURJTMIESA-N N-(1-Carboxymethyl)-L-lysine Chemical compound NCCCC[C@@H](C(O)=O)NCC(O)=O OQVOZFPJUCUPLW-LURJTMIESA-N 0.000 description 73
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 26
- 238000000034 method Methods 0.000 description 21
- 238000011160 research Methods 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 16
- 230000000813 microbial effect Effects 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 14
- 244000057717 Streptococcus lactis Species 0.000 description 13
- 235000014655 lactic acid Nutrition 0.000 description 13
- 239000004310 lactic acid Substances 0.000 description 13
- 108020004465 16S ribosomal RNA Proteins 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 241000186684 Lactobacillus pentosus Species 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108010076119 Caseins Proteins 0.000 description 7
- 102000011632 Caseins Human genes 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000008520 organization Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 239000005018 casein Substances 0.000 description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 6
- 235000021240 caseins Nutrition 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 230000036252 glycation Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 239000006872 mrs medium Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 108010050327 trypticase-soy broth Proteins 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 238000010835 comparative analysis Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000001974 tryptic soy broth Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 208000002249 Diabetes Complications Diseases 0.000 description 4
- 206010012655 Diabetic complications Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- -1 N-carboxyethyl lysine (N-carboxyethyl lysine) Chemical compound 0.000 description 4
- 229920002472 Starch Chemical class 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000021109 kimchi Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- UENLDOJJKXLRJI-ZETCQYMHSA-N (2s)-6-amino-2-(2-carboxyethylamino)hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NCCC(O)=O UENLDOJJKXLRJI-ZETCQYMHSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 244000294411 Mirabilis expansa Species 0.000 description 3
- 235000015429 Mirabilis expansa Nutrition 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 235000013536 miso Nutrition 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000013555 soy sauce Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000010757 Reduction Activity Effects 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 2
- DCPBQSFZQHFSMR-QMMMGPOBSA-N argpyrimidine Chemical compound CC1=NC(NCCC[C@H](N)C(O)=O)=NC(C)=C1O DCPBQSFZQHFSMR-QMMMGPOBSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- 229920002678 cellulose Chemical class 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- AYEKKSTZQYEZPU-RYUDHWBXSA-N pentosidine Chemical compound OC(=O)[C@@H](N)CCCCN1C=CC=C2N=C(NCCC[C@H](N)C(O)=O)N=C12 AYEKKSTZQYEZPU-RYUDHWBXSA-N 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000004460 silage Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001104473 Lactobacillus pentosus DSM 20314 Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Chemical class 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/167—Pentosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/231—Lactis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
- C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Husbandry (AREA)
- Physiology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- General Preparation And Processing Of Foods (AREA)
Description
本発明のまた他の目的は、本発明の前記新菌株、その破砕物またはその培養物を有効成分として含む、終末糖化産物関連疾患の予防または治療用の薬学的組成物を提供することにある。
終末糖化産物の低減活性を有する新菌株の分離および同定
<1−1>新菌株ラクトコッカス・ラクチスKF140の分離および同定
本発明者らは、終末糖化産物の低減活性を有する新しい菌株をキムチから分離するために次のような実験を行った。キムチを0.85%生理食塩水に懸濁し、懸濁液の一部をMRS固体培地に塗抹した後に37℃で培養した。培養後、形成されたコロニーを取ってMRS培地に画線培養して、汚染されていない純粋な単一コロニーを確保した。確保された菌株から16S rDNAを分離してシークエンシング分析を行った。
終末糖化産物の低減活性を有する新しい菌株を味噌から分離するために次のような実験を行った。味噌を0.85%生理食塩水に懸濁し、懸濁液の一部をTSB固体培地に塗抹した後に37℃で培養した。培養後、形成されたコロニーを取ってTSB培地に画線培養して、汚染されていない純粋な単一コロニーを確保した。確保された菌株から16S rDNAを分離してシークエンシング分析を行った。
キムチからラクトバチルス・パラカゼイKF00816菌株を分離および同定し、伝統式で製造されたキムチを0.85%生理食塩水に懸濁し、懸濁液の一部をMRS固体培地に塗抹した後に37℃で培養した。培養後、形成されたコロニーを取ってMRS培地に画線培養して、汚染されていない純粋な単一コロニーを確保した。確保された菌株から16S rDNAを分離してシークエンシング分析を行った。
終末糖化産物の低減活性を有するラクトバチルス・ペントーサスKF8菌株は伝統式の醤油から分離し、伝統式の醤油を0.85%生理食塩水に懸濁し、懸濁液の一部をMRS固体培地に塗抹した後に37℃で培養した。培養後、形成されたコロニーを取ってMRS培地に画線培養して、汚染されていない純粋な単一コロニーを確保した。確保された菌株から16S rDNAを分離してシークエンシング分析を行った。
本発明の新菌株の終末糖化産物の低減効能の分析
本発明者らは、前記実施例1において分離および同定した4個の新菌株が各々終末糖化産物の低減効能があるか否かを分析するために、牛乳に含まれた終末糖化産物に対する低減活性の程度を次のような方法によって確認した。
本発明の新菌株が非蛍光性の終末糖化産物の一種類であるCML(Nε−(Carboxymethyl)−L−lysine)を低減させる活性があるか否かを分析するためにCML含有食品を製造した。すなわち、牛乳の熱処理工程中に生成されるCMLを低減するために乳タンパク質であるカゼインと乳糖であるラクトースを用い、sodium caseinateとD−lactoseは(株)ES食品原料とSigma−Aldrichから各々購入して用いた。牛乳内のカゼインとラクトースの比率を考慮して牛乳タンパク質(カゼイン)と糖(ラクトース)を1:7の比率で混ぜて140℃の温度で80分間反応し、それを本発明の新菌株に対するCML低減効能の評価に用いた。この時、カゼインとラクトースのメイラード反応によるCML含量は8.24ug/mLとして確認された。
本発明に係る新菌株のCML低減効能を下記表1に記載された他の菌株および商用化されたプロバイオティクス製品を対照群にして分析を行った。下記表1の対照群として用いられた他の菌株としては韓国食品研究院の伝統食品微生物菌株銀行から購入したものを用い、プロバイオティクス製品としては市販中のものを購入して用い、プロバイオティクス製品は図1に示す。また、下記実験に用いられた菌株を培養するための培地はDifco社から購入し、乳酸菌株の培養のためにLactobacilli MRS agarとLactobacilli MRS brothを用い、バチルス属菌株の培養培地としてTSA(tryptic soy agar)とTSB(tryptic soy broth)を用いた。乳酸菌およびバチルス菌のCML低減のための本培養にはM9 minimal medium(MB cell)を用い、M9培地を製造する時、glucose 2g/L、CaCl2 0.015g/L、MgSO4 0.5g/Lを添加して用いた。
表1の乳酸菌およびプロバイオティクス製品をCMLが含まれた培養液において24時間本培養させた後、Nε−(carboxymethyl)lysine(CML)の変化量をCML ELISA kit(CircuLex、Ina、Nagano、Japan)を用いて測定した。CML−BSAで事前コーティングされた96wellに上清または標準試料とanti−CML−adduct monoclonal antibodyを添加して室温で1時間反応させた。洗浄バッファで4回洗浄した後、HRP conjugated detection antibody 100μlを添加して1時間反応させた後、洗浄バッファで4回洗浄し、基質含有溶液100μlを添加して20分間光を遮断した条件下で反応させた後、停止液100μlを添加し、マイクロプレートリーダーを用いて450nmで吸光度を測定し、その結果を下記表に示す。この時、下記表2において、陰性対照群(CON;control)は乳酸菌を全く添加していない前記<2−1>のメイラード反応で測定されたCMLが8.24ug/mL含量で含まれた群を用いたものであり、陰性対照群をCML含量100%に基準にして測定された結果である。
CML標準形式を用いた本発明に係る新菌株の終末糖化産物の低減効能の検証
前記実施例の結果から、本発明者らは、本発明の新菌株が従来のCML低減活性を有する菌株および市販品に比べて遥かに優れたCML低減効能があることを確認した。そこで、CML低減効能の再検証のために、終末糖化産物のうち最も代表的な非蛍光性の終末糖化産物であるNε−(1−carboxymethyl)−L−lysine(CAS:5746−04−3)をSanta Cruz Biotechnology社から購入し、その低減活性を再度分析した。純度99%のCML標準形式を用い、CMLの低減分析は前記実施例2と同様の方法により分析を行った。
動物実験を通じた本発明の新菌株の血中CML低減効能の分析
さらに、本発明者らは、動物実験を通じて、本発明の新菌株を用いる場合、直接的に血中内CMLの含量を低減できるか否かを確認する実験を行った。このために、牛乳に含まれたタンパク質成分であるカゼインと糖成分であるラクトースのメイラード反応によるCML高含有食品を前記実施例で記述された方法により製造した後、それをSDマウス(6週齢、雄)に摂取させた後、血中CML含量の変化を確認し、この時、1週間は本発明の新菌株を各々50mg/kg摂取させ、12時間の空腹状態を維持したラットにCML高含有食品を摂取させた後、8時間の経過後に血中CML濃度を測定した。また、陰性対照群としては、本発明の新菌株を摂取させず、CML高含有食品だけを摂取させた群を用いた。
寄託機関名:韓国微生物保存センター(国外)
受託番号:KCCM11997P
受託日時:20170324
寄託機関名:韓国微生物保存センター(国外)
受託番号:KCCM11998P
受託日時:20170324
寄託機関名:韓国微生物保存センター(国外)
受託番号:KCCM11673P
受託日時:20150306
寄託機関名:韓国微生物保存センター(国外)
受託番号:KCCM11981P
受託日時:20170224
Claims (10)
- ラクトコッカス・ラクチスKF140(受託番号KCCM11673P)菌株、バチルス・サブティリスKF11(受託番号KCCM11981P)菌株、ラクトバチルス・ペントーサスKF8(受託番号KCCM11997P)菌株およびラクトバチルス・パラカゼイKF00816(受託番号KCCM11998P)菌株からなる群の中から選択されることを特徴とする、終末糖化産物(AGEs;Advanced glycation end products)の低減活性を有する新菌株。
- 前記終末糖化産物(AGEs;Advanced glycation end products)は、非蛍光性の終末糖化産物であることを特徴とする、請求項1に記載の終末糖化産物の低減活性を有する新菌株。
- 請求項1に記載の新菌株、その破砕物またはその培養物を有効成分として含むことを特徴とする、終末糖化産物の低減活性を有する食品組成物。
- 前記組成物は、終末糖化産物により引き起こされる糖尿病、慢性腎臓疾患、心臓疾患、血管疾患、糖尿病性網膜症(retinopathy)、糖尿病性神経障害(diabetic neuropathy)、糖尿病性白内障(cataract)または糖尿病性腎症(nephropathy)を予防または改善することを特徴とする、請求項3に記載の食品組成物。
- 請求項1に記載の新菌株、その破砕物またはその培養物を有効成分として含むことを特徴とする、終末糖化産物関連疾患の予防または治療用の薬学的組成物。
- 前記疾患は、糖尿病、慢性腎臓疾患、心臓疾患、血管疾患、糖尿病性網膜症(retinopathy)、糖尿病性神経障害(diabetic neuropathy)、糖尿病性白内障(cataract)および糖尿病性腎症(nephropathy)からなる群の中から選択されることを特徴とする、請求項5に記載の終末糖化産物関連疾患の予防または治療用の薬学的組成物。
- 請求項1に記載の新菌株、その破砕物またはその培養物を有効成分として含むことを特徴とする、整腸用組成物。
- 請求項1に記載の新菌株、その破砕物またはその培養物を有効成分として含むことを特徴とする、プロバイオティクス組成物。
- 請求項1に記載の新菌株、その破砕物またはその培養物を有効成分として含むことを特徴とする、飼料用組成物。
- 請求項1に記載の新菌株、その破砕物またはその培養物を有効成分として含むことを特徴とする、発酵製品。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0044949 | 2017-04-06 | ||
KR10-2017-0044938 | 2017-04-06 | ||
KR1020170044949A KR101841023B1 (ko) | 2017-04-06 | 2017-04-06 | 최종당화산물 저감 활성을 갖는 신규한 바실러스 서브틸리스 균주 및 이의 용도 |
KR1020170044938A KR101841021B1 (ko) | 2017-04-06 | 2017-04-06 | 최종당화산물 저감 활성을 갖는 신규한 락토코쿠스 락티스 균주 및 이의 용도 |
KR1020170079735A KR101869740B1 (ko) | 2017-06-23 | 2017-06-23 | 최종당화산물 저감 활성을 갖는 신규한 락토바실러스 파라카제이 균주 및 이의 용도 |
KR10-2017-0079735 | 2017-06-23 | ||
KR10-2017-0079726 | 2017-06-23 | ||
KR1020170079726A KR101869739B1 (ko) | 2017-06-23 | 2017-06-23 | 최종당화산물 저감 활성을 갖는 신규한 락토바실러스 펜토서스 균주 및 이의 용도 |
PCT/KR2018/004076 WO2018186710A1 (ko) | 2017-04-06 | 2018-04-06 | 최종당화산물 저감 활성을 갖는 신규한 균주 및 이의 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020515296A JP2020515296A (ja) | 2020-05-28 |
JP6880307B2 true JP6880307B2 (ja) | 2021-06-02 |
Family
ID=63712263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020504082A Active JP6880307B2 (ja) | 2017-04-06 | 2018-04-06 | 終末糖化産物の低減活性を有する新規な菌株およびその用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20200270709A1 (ja) |
EP (1) | EP3611252A4 (ja) |
JP (1) | JP6880307B2 (ja) |
CN (1) | CN110506106A (ja) |
AU (1) | AU2018249789B2 (ja) |
BR (1) | BR112019021036A2 (ja) |
CA (1) | CA3058383C (ja) |
WO (1) | WO2018186710A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220211781A1 (en) * | 2019-05-14 | 2022-07-07 | Korea Food Research Institute | Strain showing liver function improving activity, and use thereof |
CN112237590A (zh) * | 2019-07-19 | 2021-01-19 | 百岳特生物技术(上海)有限公司 | 台湾藜汁液及其用途以及减脂组合物 |
AU2020204029A1 (en) * | 2020-06-17 | 2022-01-20 | Korea Food Research Institute | Lactobacillus paracasei AO356 strain having anti-obesity activity and composition when used for preventing, alleviating or treating obesity including the same |
US11278579B2 (en) * | 2020-06-17 | 2022-03-22 | Korea Food Research Institute | Lactobacillus paracasei AO356 strain having anti-obesity activity and method for preventing, alleviating or treating obesity using the same |
JP7300121B2 (ja) * | 2020-07-07 | 2023-06-29 | マイクロアルジェコーポレーション株式会社 | 抗糖化用組成物、及び抗糖化用組成物の製造方法 |
CN115572701B (zh) * | 2022-11-21 | 2023-03-10 | 广东海天创新技术有限公司 | 一株副干酪乳杆菌及其应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007284360A (ja) * | 2006-04-13 | 2007-11-01 | Mitsukan Group Honsha:Kk | 乳酸菌由来のppar依存的遺伝子転写活性化組成物 |
KR100889300B1 (ko) * | 2007-06-05 | 2009-03-18 | 수원대학교산학협력단 | 바실러스 서브틸리스 kk71 균주 및 이의 배양액을유효성분으로 함유하는 혈당강하용 조성물 |
JP5150722B2 (ja) * | 2008-04-25 | 2013-02-27 | 亀田製菓株式会社 | 抗アレルギー作用を有する新規乳酸菌と、該乳酸菌を含む抗アレルギー剤、食品及び医薬品組成物と、前記抗アレルギー剤の製造方法 |
ES2378839T3 (es) * | 2008-05-16 | 2012-04-18 | Nestec S.A. | Lactobacillus paracasei y control del peso |
KR101226548B1 (ko) * | 2011-01-07 | 2013-01-28 | 대구대학교 산학협력단 | 바실러스 속 kh-15의 콩 발효물을 유효성분으로 포함하는 당뇨병 예방 및 치료용 조성물 |
JP5940872B2 (ja) * | 2011-07-01 | 2016-06-29 | 株式会社ラフィーネインターナショナル | 抗糖尿病組成物及び飲食品 |
JP4918173B1 (ja) * | 2011-09-13 | 2012-04-18 | あづま食品株式会社 | 新規納豆菌及びこれを用いて製造した納豆 |
KR101412210B1 (ko) * | 2012-10-19 | 2014-06-27 | 한국식품연구원 | 바실러스 서브틸리스 서브스페시스 인아쿠오소룸 fa 0718을 포함하는 항당뇨 효과가 증강된 콩발효물 및 이의 제조방법 |
KR102355751B1 (ko) * | 2013-07-05 | 2022-01-26 | 가부시키가이샤 야쿠르트 혼샤 | 펜토시딘 생성 저해제 |
JP5935155B2 (ja) * | 2014-03-20 | 2016-06-15 | 株式会社Like Todo Japan製薬 | 抗糖化剤の製造方法 |
KR101708173B1 (ko) * | 2015-03-06 | 2017-02-21 | 경희대학교 산학협력단 | 혈당 조절 효능을 갖는 신규 유산균 및 이의 용도 |
KR101724126B1 (ko) * | 2015-08-13 | 2017-04-10 | 한국식품연구원 | 락토코쿠스 락티스(Lactococcus lactis)를 유효성분으로 포함하는 Th1-매개 면역 질환, Th17-매개 면역 질환 또는 Th2-매개 면역 질환의 예방, 개선 또는 치료용 조성물 |
KR101841023B1 (ko) * | 2017-04-06 | 2018-03-22 | 한국식품연구원 | 최종당화산물 저감 활성을 갖는 신규한 바실러스 서브틸리스 균주 및 이의 용도 |
KR101841021B1 (ko) * | 2017-04-06 | 2018-03-22 | 한국식품연구원 | 최종당화산물 저감 활성을 갖는 신규한 락토코쿠스 락티스 균주 및 이의 용도 |
-
2018
- 2018-04-06 WO PCT/KR2018/004076 patent/WO2018186710A1/ko unknown
- 2018-04-06 EP EP18781871.1A patent/EP3611252A4/en active Pending
- 2018-04-06 CA CA3058383A patent/CA3058383C/en active Active
- 2018-04-06 CN CN201880023333.2A patent/CN110506106A/zh active Pending
- 2018-04-06 BR BR112019021036-9A patent/BR112019021036A2/pt unknown
- 2018-04-06 JP JP2020504082A patent/JP6880307B2/ja active Active
- 2018-04-06 AU AU2018249789A patent/AU2018249789B2/en active Active
- 2018-04-06 US US16/500,913 patent/US20200270709A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2018249789A1 (en) | 2019-10-17 |
BR112019021036A2 (pt) | 2020-05-12 |
JP2020515296A (ja) | 2020-05-28 |
EP3611252A1 (en) | 2020-02-19 |
CN110506106A (zh) | 2019-11-26 |
EP3611252A4 (en) | 2021-05-05 |
US20200270709A1 (en) | 2020-08-27 |
CA3058383C (en) | 2023-09-05 |
CA3058383A1 (en) | 2018-10-11 |
WO2018186710A1 (ko) | 2018-10-11 |
AU2018249789B2 (en) | 2021-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6880307B2 (ja) | 終末糖化産物の低減活性を有する新規な菌株およびその用途 | |
KR102230571B1 (ko) | 비형광성 최종당화산물 억제용 조성물 및 이의 용도 | |
CN109718255B (zh) | 一种消除宿醉酶粉末的制备方法和含有该成分的消除宿醉用组合物 | |
KR101761379B1 (ko) | 다기능 신규 균주 락토바실러스 사케이 k040706 및 이의 배양 방법 | |
KR102153080B1 (ko) | 신규한 락토바실러스 살리바리우스 hem 1047 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물 | |
KR101492650B1 (ko) | 혈중 아디포넥틴 농도 증가 촉진 및/또는 감소 억제제 및 내장 지방 축적 억제제 | |
KR101869740B1 (ko) | 최종당화산물 저감 활성을 갖는 신규한 락토바실러스 파라카제이 균주 및 이의 용도 | |
KR101841023B1 (ko) | 최종당화산물 저감 활성을 갖는 신규한 바실러스 서브틸리스 균주 및 이의 용도 | |
KR101841021B1 (ko) | 최종당화산물 저감 활성을 갖는 신규한 락토코쿠스 락티스 균주 및 이의 용도 | |
KR102174095B1 (ko) | 신규한 엔테로코커스 패시움 hem 200 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물 | |
KR101869739B1 (ko) | 최종당화산물 저감 활성을 갖는 신규한 락토바실러스 펜토서스 균주 및 이의 용도 | |
KR102275115B1 (ko) | 프로바이오틱 활성을 갖는 사카로마이세스 세레비지애 보울라디03 신균주 및 이의 용도 | |
KR101473475B1 (ko) | 신규한 락토바실러스 속 미생물 및 이를 이용한 풍미가 향상된 대추발효물의 제조 방법 | |
KR102215592B1 (ko) | 신규한 락토바실러스 퍼멘텀 hem 1036 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물 | |
JP5421348B2 (ja) | ラクトバシルス属微生物で発酵させた菊芋発酵抽出物を有効成分として含む糖尿病の予防及び治療用薬学的組成物(CompositioncontainingextractofJerusalemartichokefermentedbyLactobacillussp.forpreventingandtreatingdiabetesmellitus) | |
KR101627806B1 (ko) | 락토바실러스 속 균주의 면역증강 활성을 증가시키는 배양 방법 | |
KR101182606B1 (ko) | 신규한 면역증강 효과가 있는 바이셀라 속 균주 및 이의 용도 | |
KR101327295B1 (ko) | 신규한 면역기능 증진 활성이 있는 엔테로코커스 속 균주 및 이의 용도 | |
KR101878525B1 (ko) | Qol 개선 또는 지속제 | |
EP3701953A1 (en) | Composition for preventing or alleviating nonalcoholic fatty liver disease | |
JP2009114111A (ja) | カルシウム吸収促進剤 | |
KR102215596B1 (ko) | 신규한 스트렙토코커스 써모필러스 hem 14 균주, 및 상기 균주 또는 이의 배양물을 포함하는 장내 환경 개선용 조성물 | |
EP3892331A1 (en) | Composition for suppressing norovirus infection | |
KR101467362B1 (ko) | 신규한 락토바실러스 속 미생물 및 이를 이용한 풍미가 향상된 대추발효물의 제조 방법 | |
EP4166149A1 (en) | Mitochondrial function-improving composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20191004 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191004 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201005 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210305 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210405 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210430 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6880307 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |